District-based biotech company Regenxbio has raised a $30 million funding round to move its drugs into clinical trials. T
he Washington Post reports the company’s gene therapy technology, which introduces healthy genes into patients suffering from genetic disorders, will initially focus on treating diseases affecting the central nervous system and eyes. However, executives tell the Post the treatment could be used on as many as 50 different diseases.
{iframe}http://www.bizjournals.com/washington/morning_call/2015/01/biotech-regenxbio-lands-30-million-investment-to.html{/iframe}